1,657 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Friedenthal Financial

Friedenthal Financial acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,657 shares of the company’s stock, valued at approximately $1,059,000.

Other large investors also recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $29,000. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $30,000. Armstrong Advisory Group Inc. boosted its stake in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $36,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several recent research reports. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 29th. Morgan Stanley lifted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. UBS Group raised their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $763.50.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 2.8%

IDXX opened at $682.31 on Wednesday. The firm has a market cap of $54.48 billion, a P/E ratio of 54.11, a price-to-earnings-growth ratio of 4.19 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The business has a 50 day moving average price of $692.65 and a 200 day moving average price of $629.36. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company posted $2.80 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.